Human medicines European public assessment report (EPAR): Ruxience, rituximab, Date of authorisation: 01/04/2020, Revision: 13, Status: Authorised

Submitted by Anonymous (not verified) on 14 July 2025 - 15:57

Human medicines European public assessment report (EPAR): Ruxience, rituximab, Date of authorisation: 01/04/2020, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): Fluad, influenza vaccine (surface antigen, inactivated, adjuvanted), Date of authorisation: 15/11/2024, Revision: 1, Status: Authorised

Submitted by Anonymous (not verified) on 14 July 2025 - 15:22

Human medicines European public assessment report (EPAR): Fluad, influenza vaccine (surface antigen, inactivated, adjuvanted), Date of authorisation: 15/11/2024, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Fluenz, influenza vaccine (live attenuated, nasal), Date of authorisation: 03/06/2024, Revision: 5, Status: Authorised

Submitted by Anonymous (not verified) on 14 July 2025 - 15:11

Human medicines European public assessment report (EPAR): Fluenz, influenza vaccine (live attenuated, nasal), Date of authorisation: 03/06/2024, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Febuxostat Viatris (previously Febuxostat Mylan), febuxostat, Date of authorisation: 15/06/2017, Revision: 14, Status: Authorised

Submitted by Anonymous (not verified) on 14 July 2025 - 13:48

Human medicines European public assessment report (EPAR): Febuxostat Viatris (previously Febuxostat Mylan), febuxostat, Date of authorisation: 15/06/2017, Revision: 14, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More